Tin tức & Cập nhật
Xem bài viết Ung thư
Xem
NATALEE update: Ribociclib + NSAI well tolerated
Latest findings from the ongoing phase III NATALEE trial have shown that 3-year treatment with adjuvant ribociclib, in combination with a nonsteroidal aromatase inhibitor (NSAI), remained well tolerated in patients with HR+/HER2- early-stage breast cancer (EBC).
DESTINY-Breast03 reports longest OS in previously treated HER2-positive mBC
Long-term follow-up of the DESTINY-Breast03 trial has reported a median overall survival (OS) of 52.6 months with trastuzumab deruxtecan (T-DXd), representing the longest reported OS in previously treated HER2-positive metastatic breast cancer (mBC) to date.
TMI, fludarabine, melphalan pass phase I trial as conditioning therapy in multiple myeloma
Fludarabine, melphalan, and total marrow irradiation (TMI) 900 cGy may be utilized as conditioning for allogeneic stem cell transplantation in patients with high-risk or relapsed/refractory multiple myeloma, as shown in a phase I trial.
Nomogram predicts acute radiation enteritis in cervical cancer
A nomogram model displays a decent performance in predicting grade ≥2 acute radiation enteritis (ARE) among patients with cervical cancer receiving concurrent chemoradiotherapy, a study has shown.
![[Infographic] Tháng 7 - Cùng nâng cao nhận thức về Sarcoma](https://cdn.mspuat.mims.com/images/articles/nang-cao-nhan-thuc-ve-sarcoma-73399196-70ef-4aa6-897d-27a39151b4ec-square.png)
![[Infographic] Một số câu hỏi thường gặp về Nghiên cứu WHI – Sáng kiến về sức khỏe phụ nữ](https://cdn.mspuat.mims.com/images/articles/nghien-cuu-whi-69ee3539-1c12-4ced-98c2-25fa5fbdaf89-square.png)
![[NEWS] Dịch vụ Y tế Quốc gia Anh (NHS): bệnh nhân đầu tiên được thử nghiệm điều trị với vaccine cá nhân hóa chống lại ung thư](https://cdn.mspuat.mims.com/images/articles/vaccine-ung-thu-đai-truc-trang-3b9416a5-e51d-497e-836b-f6f4c0d4606f-square.png)